Regulus Therapeutics Inc.
RGLS
Ранг среди акций
#17328
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Цена акции
$8.16
Последняя синхронизация: 2025-06-26
Рыночная капитализация
$234.57M
Изменение (1 день)
0.00%
Изменение (1 год)
-88.86%
Страна
US
Торговля Regulus Therapeutics Inc. (RGLS)
Категория
Healthcare
Коэффициент P/B для Regulus Therapeutics Inc. (RGLS)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Regulus Therapeutics Inc., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Regulus Therapeutics Inc. с 2026 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| Недостаточно данных для указанных дат. | ||
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
